It has also been licensed to sell starting materials to patients wishing to grow their own medicine
Showing 25 of 1368
WeedMD is the latest advanced cannabis company to trade on the Canadian market
Bard will be bought by fellow titan Becton, Dickinson and Co after the pair agreed to combine in an eye watering $24bn deal.
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers
The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections
Most recently, he was finance director at Nelipak Packaging, a private equity backed medical packaging manufacturer
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
In separate statements, both companies said there was no certainty the discussions would lead to a deal
The device can give accurate and rapid volumetric information about all four chambers of the heart
It will now be easier for US investors to trade the Canadian company's shares
Jazz will grant Hikma and its wholly-owned subsidiary West-Ward Pharmaceuticals Corp the right to sell an authorised generic version of Xyrem in the US from the beginning of January 2023
The company is well-placed as it looks forward to the continuation of its Phase 2 proof of concept trial for its lead utrophin modulator, ezutromid, and preparation work on its ridinilazole antibiotic
Akers Biosciences Inc certainly hasn't stood still this year and today received an endorsement for its over-the-counter cholesterol self-test.
Summit has now applied for regulatory approval to extend PhaseOut DMD in the UK and USA
Heart analysis tech specialist VentriPoint Diagnostics (CVE:VPT) said it had closed its placing and raised $3.36mln in the process to be used for marketing its VMS-Plus product.
The company still made a net loss, but this narrowed to US$2.78mln from US$5.71mln the year before.
Total revenue for the year to end December came in at $1.97mln compared to $1.79mln in the same period of 2015.
CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
Caladrius is selling out to the junior partner in the joint venture and trousering US$75mln
Shares in Hikma Pharmaceuticals have gained today after it reported a better-than-expected drop in full year profit
Editas is one of three companies currently locked in a courtroom battle over the ownership of the gene-editing technique CRISPR
Billionaire investor Bill Ackman, via Pershing Square Capital Management, has retreated out of the drugmaker.
THC is expecting net profit of over $1 million in 2017.
VolitionRx Limited's senior management team will ring the closing bell at the New York Stock Exchange (NYSE) 1600 EDT
The broker Rodman looked at VolitionRx;s results and the potential ahead